← Back to Search

Genistein for Bladder Cancer Side Effects

Phase 2
Waitlist Available
Led By Omer Kucuk, MD
Research Sponsored by Emory University
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Diagnosis of superficial bladder cancer
18 years or older
Must not have
Diagnosis of muscle-invasive bladder cancer
Unwillingness to follow study protocol and compliance procedures
Timeline
Screening 3 weeks
Treatment Varies
Follow Up at 10 weeks of treatment.

Summary

This trial is testing whether a soy-based pill called genistein can help reduce side effects and improve the effectiveness of bladder cancer treatment. It targets patients with non-muscle invasive bladder cancer who are undergoing BCG therapy. Genistein may reduce inflammation and boost the immune system, making the treatment more comfortable and effective. Genistein, a soy compound, has been observed to inhibit bladder cancer growth.

Who is the study for?
This trial is for adults with non-invasive bladder cancer scheduled for BCG therapy. Participants must be willing to give blood samples, maintain a pill diary, and consent to the study. It's not open to pregnant individuals, those unwilling to follow the protocol, with concurrent second active cancer, muscle-invasive bladder cancer, or compromised immune systems.
What is being tested?
The study tests if genistein (a soybean chemical) can reduce urinary tract symptoms from intravesical therapy in bladder cancer treatment compared to a placebo (sugar pill). Patients are randomly assigned to either take genistein or placebo over approximately four and a half months.
What are the potential side effects?
While specific side effects of genistein aren't detailed here, it's generally being tested for its potential benefits on urinary symptoms related to bladder cancer treatments rather than adverse effects.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I have been diagnosed with early-stage bladder cancer.
Select...
I am 18 years old or older.
Select...
I am scheduled for BCG therapy for bladder cancer.

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:
Select...
I have been diagnosed with bladder cancer that has grown into the bladder muscle.
Select...
I am willing to follow the study's rules and procedures.
Select...
I am currently receiving immunotherapy or chemotherapy.
Select...
I currently have more than one type of cancer.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~at 10 weeks of treatment.
This trial's timeline: 3 weeks for screening, Varies for treatment, and at 10 weeks of treatment. for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Change in Severity of Urinary Symptoms as Determined by the The International Prostate Symptom Score (IPSS) Questionnaire Score.
Secondary study objectives
Number of Participants With Cancer Recurrence Determined at 10-week Biopsy.

Trial Design

2Treatment groups
Experimental Treatment
Placebo Group
Group I: Genistein supplementExperimental Treatment1 Intervention
30 mg of genistein supplement by mouth three times daily (PO TID) for 10 weeks.
Group II: Sugar pillPlacebo Group1 Intervention
Patients will be given placebo pills for 10 weeks.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Genistein
2005
Completed Phase 3
~510

Research Highlights

Information in this section is not a recommendation. We encourage patients to speak with their healthcare team when evaluating any treatment decision.
Mechanism Of Action
Side Effect Profile
Prior Approvals
Other Research
Common treatments for bladder cancer include intravesical therapy, chemotherapy, and emerging agents like genistein. Intravesical therapy involves directly administering therapeutic agents into the bladder to target cancer cells locally, reducing systemic side effects. Chemotherapy, often using agents like cisplatin, works by damaging the DNA of rapidly dividing cancer cells, leading to cell death. Genistein, a soy-derived compound, is being studied for its potential to reduce lower urinary tract symptoms and impact recurrence rates by modulating cellular pathways involved in cancer progression. These treatments are crucial for bladder cancer patients as they aim to effectively manage the disease while minimizing adverse effects and improving quality of life.
Effects of Epigallocatechin Gallate (EGCG) on Urinary Bladder Urothelial Carcinoma-Next-Generation Sequencing and Bioinformatics Approaches.p53 and retinoblastoma pathways in bladder cancer.

Find a Location

Who is running the clinical trial?

National Cancer Institute (NCI)NIH
13,879 Previous Clinical Trials
41,013,210 Total Patients Enrolled
National Institutes of Health (NIH)NIH
2,798 Previous Clinical Trials
8,141,489 Total Patients Enrolled
Emory UniversityLead Sponsor
1,688 Previous Clinical Trials
2,602,909 Total Patients Enrolled

Media Library

Genistein Clinical Trial Eligibility Overview. Trial Name: NCT01489813 — Phase 2
Bladder Cancer Research Study Groups: Genistein supplement, Sugar pill
Bladder Cancer Clinical Trial 2023: Genistein Highlights & Side Effects. Trial Name: NCT01489813 — Phase 2
Genistein 2023 Treatment Timeline for Medical Study. Trial Name: NCT01489813 — Phase 2
~4 spots leftby Oct 2025